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Abstract
Introduction: COPD is one of the most important lung diseases. It is responsible for significant proportion of outpatients
pulmonary clinics visits. Data on outpatients care of COPD patients in Poland are limited. This article presents design of the
KOMPAS study and basic results relating to COPD patients.
Material and methods: The aim of this prospective study was to describe population of patients with COPD treated by
specialists, and to characterize methods of care used in various COPD stages. Participating physicians used pocket PCs
equipped with specially developed software to collect COPD patients’ data.
Results: Data on 2958 COPD patients were analyzed. 2/3 of patients were males. Mean patients age was 63 years and mean
FEV1 — 57% of predicted value. 86% of all subjects underwent spirometry during the first visit or the previous 6 months.
Cough and exertional dyspnoea were the most frequently reported COPD symptoms (about 80% of patients). At the first visit
32% of subjects were current smokers and 51% were ex-smokers. 17% of all study patients have never smoked. Before
inclusion 2/3 of patients were treated with bronchodilatator, and about 1/3 with inhaled steroid. After entering the study,
over 90% received bronchodilatator and more than 2/3 received inhaled steroid. Differences in treatment between stages of
COPD based on its severity were relatively small.
Conclusions: results of the KOMPAS study provide basic information about COPD outpatients care in Poland. These data,
especially concerning physicians’ compliance with current COPD guidelines, may be useful in planning undergraduate/
/postgraduate training for physicians and for those who are responsible for health resource allocation.
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Introduction
Chronic obstructive pulmonary disease is one
of the most common chronic respiratory diseases.
Among individuals over 40 years of age, it consti-
tutes one of the most important causes of morbidi-
ty and mortality [1, 2]. Prevalence of COPD is esti-
mated to be at least 5% of general population, but
because the disease affects mainly elderly people,
in the adult population its prevalence exceeds 10%
[3]. According to the latest studies led by the Bur-
den of Obstructive Lung Disease (BOLD) Initiative,
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cians, treating COPD and asthma patients) were
invited to participate in the study. In order to beco-
me the study investigator, each physician had to
include at least 10 subjects and continue their ob-
servation for at least 12 months and 4 visits.
The KOMPAS study included COPD and asth-
ma patients treated in outpatient clinics, however
this article focuses only on COPD patients. Data
on asthma patients will be presented in a separate
publication.
Physicians participating in the study were
provided with pocket PCs (Dell Axim X30, Dell,
Poland), pre-loaded with software exclusively
developed for this study, including electronic ques-
tionnaire automatically saving patient informa-
tion. The questionnaire comprised questions on
COPD severity stage, the presence of cough, the
presence and intensity of exertional and noctur-
nal dypnoea, the presence of right-heart failure (ty-
pical signs and symptoms, as judged by physi-
cians), burden of the disease as judged by the pa-
tients, spirometry results, information about tobac-
co smoking habit and physician’s satisfaction of
treatment results. COPD diagnosis and assignment
of severity stage were based on a judgment of cli-
nicians participating in the study. Written instruc-
tions for physicians suggested using GOLD guide-
lines classification of severity, based on post-bron-
chodilatator spirometry results (Stage 1: FEV1/FVC
< 0.7 and FEV1 ≥ 80% pred.; Stage 2: FEV1/FVC
< 0.7 and FEV1 ≥ 50% and < 80% pred.; Stage 3:
FEV1/FVC < 0.7 and FEV1 ≥ 30% and < 50% pred.;
Stage 4: FEV1/FVC < 0.7 and FEV1 < 30% or FEV1
< 50% and chronic respiratory insufficiency) [8].
Because during project-phase of the study GOLD,
guidelines also included COPD Stage 0 — at risk
(subjects which do not have COPD), some healthy
subjects in previous GOLD 0 Stage were included.
COPD exacerbations were diagnosed based on phy-
sicians’ judgment. Symptoms intensity was quan-
tified in 7-steps scale, where steps 1 to 7 referred
to growing intensity of symptoms (for example for
question concerning relief use of bronchodilata-
tors: 1 — never, 2 — £ 1/month, 3 — > 1/months
but < 1/week, 4 — on average 1/week, 5 — > 1/week
but < 1/day, 6 — every day, 7 — few times a day).
The questionnaire also comprised information
about current treatment and its changes. Data on tre-
atment before inclusion (based on information col-
lected at inclusion, during the 1st visit) were only
collected for subjects who previously have not been
treated by the physicians participating in the study.
Data entered by physicians were saved on the
memory cards, which were subsequently transfer-
red to the study data coordinating center. Data were
COPD prevalence in the population aged at least
40 years in Poland [4] as well as worldwide [5] can
exceed 20%. These patients often need intensive
medical care, and their treatment is expensive [6].
COPD is a reason for substantial proportion of all
outpatient visits caused by lung diseases. The pre-
valence of COPD is expected to grow in the upco-
ming years, placing more burden on the health care
systems [7].
Standards of care for COPD patients are set by
widely accepted guidelines, especially Global Ini-
tiative for Chronic Obstructive Lung Disease (GOLD)
guidelines [8]. In Poland such guidelines have been
developed by the Polish Society of Lung Diseases
[9]. Effective implementation of guidelines is im-
portant to improve of the quality of care [10]. Only
few studies aiming to describe COPD outpatient
population in Poland are available. Lack of data
concerning COPD and the lack of social awareness
of this disease is illustrated by the fact, that the last
polish Main Statistical Office (GUS) Report on
polish citizens state of health does not even men-
tion COPD [11]. The study published in 2004, ba-
sed on data collected from patients, has demonstra-
ted that COPD management (especially in stable
COPD) is often incompatible with published
guidelines (however, these data were based on ana-
lyses of only 105 cases) [12]. Optimistic results
concerning quality of care of COPD patients were
brought by the study based on the results of
questionnaire among pulmonary physicians [13].
However, quality of this study is reduced by the
response rate of only 10%. In other European coun-
tries, care of COPD patients is often at variance
with guidelines, especially in primary care settings
[14–16]. In Poland, patients care is provided lar-
gely by specialists — in 2005, 34% of all outpa-
tient visits were performed by specialists [17]. In
our country, specialists often take care not only of
the most severe cases, but also patients with mild
and moderate disease.
This article is the first of planned publications
presenting the results of the KOMPAS project. It
describes methodology of the KOMPAS study and
its main results concerning COPD subjects.
The main aim of the study was to describe the
population of patients diagnosed with COPD, cared
by pulmonologists and alergologists, and to charac-
terize the management in individual COPD stages.
Material and methods
Six hundred non-randomly chosen physicians
from all main administrative parts of Poland (mo-
stly pulmonologists, alergologists and pediatri-
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saved and kept in a way preventing identification
of patients — only patient’s code was entered and
the data from data memory card could have been
read only with individual Pocket PC of the physi-
cian who took care of the patient, or in the study
data coordinating center.
Results are presented as a mean (numerical
variables) or as a percentage (categorical variables).
Between group differences were analyzed using
student’s T test, U Mann-Whitey’s test, chi2 test and
Kruskal-Wallis test.
The study has been financed by a research
grant from AstraZeneca. Sponsor has chosen phy-
sicians participating in the study but had no in-
fluence of any other kind on study planning, data
analyzes or publication content.
Results
Characteristics of the physicians
These data apply to all participating physi-
cians. Data from 428 physicians were obtained;
women constituted 57.7%, men — 41.1% (1.2%
researchers did not provide information about their
gender). 47% physicians have had the experience
of working longer than 10 years, whereas 38.6%
— longer than 20 years. 45% have had only one
workplace; others worked in at least two workpla-
ces. Proportion of specialists in different discipli-
nes is depicted on Table 1. Alergologists have al-
most exclusively included into the study patients
with asthma (94% of their patients), whereas 46%
patients cared by pulmonologists have had COPD.
Characteristics of the patients
A total of 13 545 patients were enrolled into
the study. COPD have been diagnosed in 3315 pa-
tients (24.5% of all subjects). About 2% of all stu-
dy cases were removed from further analyses due
to unacceptable data quality. Also patients with
COPD included by pediatricians were removed
Table 1. Specialty of the doctors participating in the study
Specialty Proportion of physicians (%)
Pulmonology 40.7
Allergology 15.9
Allergology and pulmonology 0.9
Pediatrics 10.0
Pediatrics and pulmonology 10.3
Pediatrics and allergology 10.7
Pediatrics. pulmonology and allergology 6.6
No data available 4.9
Table 2. Basic characteristics of COPD patients
Men Women Total p for difference
(n = 2251) (n = 999)  (n = 3250)  between sexes
Sex 69.3% 30.7% – –
Age (years) 63.4 (SD ± 10.2) 61.7 (SD ± 10.3) 62.9 (SD ± 10.3) < 0.0000*
FEV1 (% predicted) 55.7 (SD ± 16.9) 61.3 (SD ± 17.4) 57.4 (SD ± 17.2) < 0.0000*
FEV1/FVC (%) 64.3 (SD ± 15.0) 68.9 (SD ± 15.4) 65.7 (SD ± 15.3) < 0.0000*
Subjects cared by study 69.2% 66.6% 68.4% 0.13**
doctor before inclusion
*U Mann-Whitney’s test; **chi2 test; FEV1 — forced expiratory volume; FVC — forced vital capacity; SD — standard deviation
from analyses (9% of COPD subjects). The results
presented here are based on analyses of the rema-
ining 2958 patients.
68.5% of COPD subjects were previously tre-
ated by physicians participating in the study, whe-
reas 31.5% patients were consulted by study phy-
sicians for the first time at the enrollment to the
study. Main characteristics of patients are presen-
ted in Table 2. Figure 1 depicts proportion of dif-
ferent severity stages during the first study visit.
Men were significantly older, had worse lung func-
tion (Table 2) and more severe COPD. During the
next visits proportions of COPD severity stages
were similar. Mean patients’ age was 62.9 years;
patients were significantly older in consecutive
COPD stages. During the first visit (or up to
6 month before) spirometry has been performed in
86% COPD subjects; proportion of patients with
various numbers of spirometry results during the
first 5 visits is depicted in Figure 2. FEV1 measu-
red during the first visit was significantly smaller
in patients with more severe COPD stages and with
progression of time since COPD diagnosis. In 29%
subjects FEV1/FVC was ≥ 0.7. In this group, the
proportion of women was significantly greater than
in other subjects (38% vs. 24%); they were signifi-
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cantly younger, had larger mean FEV1 and smaller
proportion were smokers. Subjects with FEV1/FVC
≥ 0.7 were less likely to have night and exertional
dyspnoea, but the proportion of subjects with
cough was similar as in subjects with FEV1/FVC
< 0.7. On consecutive visits, gradual improvement
of FEV1 has been seen (in comparison to value at
the first visit); this improvement was much more
pronounced in subjects with exacerbation at first
visit (Fig. 3). FEV1 improvement was larger in sub-
jects with initial FEV1/FVC < 0.7.
Most COPD patients have complained about
cough (83%) and exertional dyspnoea (78%). About
half of all study subjects have had nocturnal dysp-
noea attacks, whereas symptoms of right heart
failure were present in 15%. The proportions of
subjects complaining about cough were not signi-
ficantly different between COPD stages (Fig. 4).
On the contrary, percentage of subjects with noc-
turnal and exertional dyspnoea has been increasing
with disease severity. Symptoms of right heart
failure were present mainly in severe and very se-
vere COPD. The severity of symptoms, as well as
consumption of rescue drugs (both assessed in 7.
step scale) increased with growing COPD severi-
ty. Current smokers (as compared to ex- and ne-
ver-smokers) more often presented with cough
and night dyspnoea and their disease was more
troublesome (as judged by the patients). Burden
of COPD symptoms was more pronounced in pa-
tients, who were not cared by the study physicians
before inclusion.
At the first study visit, 19% of patients pre-
sented with COPD exacerbation and another 11%
have had exacerbation since the previous medical
visit. As the severity of COPD increased, larger
proportion of patients presented with exacerbation
on the first visit (Fig. 5). Proportion of exacerbations
did not differ significantly between patients with
FEV1/FVC < 0.7 and those with FEV1/FVC ≥ 0.7.
During consecutive visits proportion of patients
with COPD exacerbations was lower (Fig. 6).
During entry into the KOMPAS Study, 32%
COPD patients were current smokers, 51% were ex-
-smokers and remaining 17% have never smoked.
(Fig. 7). Among women proportion of never-smo-
kers was 33%, whereas in men — 10%. Proportion
of smokers has significantly decreased during con-
secutive visits, however this observation needs
further analyses.
Mean age, gender, severity stages distribution
and proportion of subjects who had spirometry
performed were not significantly different betwe-
en subjects cared by alergologists (n = 163) and
pulmonologists (n = 2487). Proportion of subjects
with FEV1/FVC > 0.7 was significantly larger in
subjects cared by alergologists (53% vs. 25%).
Figure 1. Proportion of COPD subjects in relation to COPD Stages (during first visit)
Figure 2. Frequency of spirometry during the first 5 visits in the
study
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Figure 4. Prevalence of COPD signs and symptoms in relation to disease stage
Figure 5. Prevalence of exacerbations during 1st visit among patients in relation to COPD stage
Figure 3. Average FEV1 values during consecutive visits (all patients)
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Treatment
Before entry into the study about 2/3 of all
patients have received any bronchodilator, and
more than a 1/3 — inhaled steroid. Data on phar-
macotherapy used by the patients before entry are
presented in Table 3. Data on treatment prescri-
bed during the 1st visit (after inclusion) are presen-
ted in Table 4. After inclusion, the study patients
were treated more intensively, and more differen-
ces in treatment were present among COPD stages
than before inclusion. More than 90% of all study
subjects have received long acting bronchodilator
and about 70% — inhaled steroid. There were no
significant differences in treatment between sub-
jects with z FEV1/FVC < 0.7 and those with FEV1/
/FVC ≥ 0.7. Inhaled steroids were used in large pro-
portion of mild COPD subjects, as well as in those
in stage 0 (“at risk”). Alergologists and pulmono-
logists used bronchodilatators in similar propor-
tion of subjects, whereas significantly more pa-
tients treated by alergologists have received inha-
led steroids (86% vs. 68%).
Discussion
This article is the first publication of the upco-
ming series, presenting results of the KOMPAS
Study (Complex Observational Study of COPD and
Asthma Patients). The study involved physicians
Figure 6. Prevalence of exacerbations during consecutive visits among all patients
Figure 7. Prevalence of tobacco smoking in COPD patients (data from 1st visit)
Filip Mejza et al., Outpatients specialist care of COPD patients
513www.pneumonologia.viamedica.pl
from all regions of Poland, most of them speciali-
sts with long work experience. Results cannot be
treated as fully representative, however, because
the study has included non-randomly selected cli-
nicians. Nevertheless, it included about 20% of
Polish pulmonologists [17] as well as large propor-
tion of alergologists and pediatricians, and thus, it
provides an important information about outpa-
tients pulmonary specialist care in Poland.
COPD subjects were predominantly male.
Analyzing the proportions of COPD severity sta-
ges one has to remember, that these results are
based mostly on patients referred to specialists,
thus the proportion of severe and very severe COPD
(32%) is larger than in the general population of
COPD subjects [4].
Over 80% of patients with spirometry perfor-
med during the 1st visit or up to 6 month prior,
proves good access to spirometry. 20% of subjects
have had spirometry performed on each of the first
5 visits. Of note, about 15% of patients did not have
spirometry performed during the first 5 visits.
COPD diagnosis, in these subjects, can be questio-
ned, however, in most of them COPD has been dia-
gnosed more than one year prior to the 1st visit.
COPD diagnosis was based on physician’s decision;
our aim was to describe population of subjects with
COPD diagnosed by physicians’, regardless of its
relationship to current guidelines. We also wan-
ted to assess, how often spirometry was used in
diagnosis of COPD and care of patients with COPD.
During the 1st visit, the proportion of smokers
among COPD subjects was similar to such propor-
tion in general population of Poland [10]. On con-
secutive visits percentage of smokers among stu-
died subjects has been declining gradually. Our
results, similarly to many recent papers on COPD
[4, 18], demonstrate that substantial proportion of
COPD subjects has never smoked tobacco. Simi-
larly to other studies women were more prevalent
in never-smokers COPD patients.
Substantial proportion of COPD subjects has
not fulfilled spirometric COPD criteria (FEV1/FVC
< 0.7). To some extent it is caused by inclusion
into the study subjects in stage 0 (stage 0 was pre-
sent in the GOLD Guidelines at the time of study
design). However, among subjects in other COPD
stages proportion of those with FEV1/FVC > 0.7 is
Table 3. Treatment in individual COPD stages before inclusion into the study. Table data apply only to patients who were
not treated by study doctors before study inclusion (n = 1027). Results presented as a proportion of all subjects
who received a drug from given class
COPD stage SABA LABA Short acting Long acting Inhaled Oral CS Methyloxanthines Expectorants
anticholinergics anticholinergics CS
At risk 10 43.3 5 0 33.3 1.7 20 11.7
Mild 15 48.5 18 0 36.5 1 18.5 9
Moderate 27.3 49.7 15.5 0 33.4 2.9 30.5 12.6
Severe 34.9 54.9 19.1 0.4 43.4 1.7 48.1 16.6
Very severe 41.5 65.9 43.9 0 46.3 9.8 61 14.6
All subjects 26.2 50.9 17.3 0.1 36.8 2.4 32.8 12.9
CS — corticosteroids; LABA — long acting b2-agonists; SABA— short acting b2-agonists
Table 4. Treatment in individual COPD stages after 1st visit (all patients, n = 3250). Results presented as a proportion of all
subjects who received a drug from given class
COPD stage SABA LABA Short acting Long acting Inhaled Oral CS Methyloxanthines Expectorants
anticholinergics anticholinergics CS
At risk 27.0 67.9 33.6 0 46.7 0 21.2 17.5
Mild 24.6 84.8 38.0 0.4 62.2 0.5 26.9 20.7
Moderate 41.2 89.7 47.6 0.7 70.2 4.8 52.9 33.3
Severe 54.9 90.5 53.7 1.6 83.9 14.1 71.1 34.9
Very severe 70.5 92.1 55.3 5.3 79.5 26.8 76.3 43.2
All subjects 43.0 88.3 47.4 1.1 71.9 7.6 53.1 31.4
CS — corticosteroids; LABA — long acting b2-agonists; SABA — short acting b2-agonists
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substantial which demonstrates discrepancy be-
tween physicians’ diagnosis and current diagno-
stic criteria in those subjects. It is probable, that
some of the study subjects, especially those cared
by alergologists (among those subjects proportion
of those with FEV1/FVC > 0.7 was significantly
larger) actually have had bronchial asthma. The
treatment used and its effectiveness did not differ
significantly between those two groups of patients
— results of the analyses of the data from conse-
cutive visits, performed after exclusion of subjects
with FEV1/FVC > 0.7 were not significantly diffe-
rent. Proportion of subjects with FEV1/FVC > 0.7
is even smaller than in some published studies
[21, 22], which could have been caused by perfor-
ming those studies in primary care settings.
Our results suggest that treatment by specia-
lists involved in the study was effective — FEV1
has been increasing and proportion of subjects
with exacerbations has been declining during con-
secutive visits. These observations were not affec-
ted by exclusion from analyses subjects with
FEV1/FVC > 0.7.
Data concerning treatment before inclusion
(concerning patients who had not been treated
earlier by the study clinicians) demonstrate that
treatment was less intensive prior to inclusion. The
proportions of patients treated with bronchodila-
tors and inhaled steroids were higher than expec-
ted, which could have been caused by selection of
study population (subjects sent for consultation to
specialists). Differences in the treatment intensity
between COPD stages were, however, relatively
small. After inclusion, the study patients were tre-
ated even more intensively, and proportion of sub-
jects treated with different drug classes were the
same as in the remaining patients (i.e. those tre-
ated by the study doctors before inclusion). Data
on treatment used by the study doctors demonstra-
te extensive use of available drugs. Most COPD
subjects have received intensive treatment. While
in severe COPD such treatment is indicated and
often necessary [8, 9], of note is the use of multi-
drug treatment in less severe cases. Relatively lar-
ge proportion of subject were treated with methyl-
xanthines. Inhaled glicocorticosteroids were used
early in the disease course, whereas current guide-
lines recommend their use in severe and very se-
vere COPD with frequent exacerbations [8]. In our
study these drugs were used in most COPD stages,
including subjects at risk of COPD. These data sug-
gest a need for continuing the activities aiming at
dissemination and implementation of evidence-
-based guidelines, accepted by polish and interna-
tional scientific societies [8, 9].
Conclusions
In conclusion, we believe that the KOMPAS
study provides basic information about secondary
and tertiary outpatient COPD care in Poland. In-
clusion of a large group of physicians and patients
constitutes to the strength of our study, allowing
description of management in different COPD sta-
ges. The limitation of the study is lack of random
selection of physicians and patients. Despite the fact
that our study included substantial proportion of
physicians of different specialties in Poland, one
cannot exclude, that management methods used by
study physicians were significantly different from
those who did not participate. Gradual improvement
in COPD symptoms and spirometry results in pa-
tients included in the study, as well as the relative-
ly small differences in treatment used in various
COPD stages are our most important observations.
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